Article Text

Download PDFPDF

223 Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases
  1. EF Thompson1,
  2. A Jamieson2,
  3. J Huvila3,
  4. S Leung4,
  5. A Lum1,
  6. C Morin5,
  7. K Ennour-Idrissi5,
  8. A Sebastianelli6,
  9. MC Renaud6,
  10. J Gregoire6,
  11. M Plante6,
  12. D Huntsman1,
  13. CB Gilks7,
  14. K Grondin5 and
  15. J Mcalpine2
  1. 1The University of British Columbia, Molecular Oncology , Vancouver, Canada
  2. 2The University of British Columbia, Gynaecologic Oncology, Vancouver, Canada
  3. 3University of Turku, Institute of Biomedicine, Turku, Finland
  4. 4The University of British Columbia, Genetic Pathology Evaluation Centre, Vancouver, Canada
  5. 5Chu De Québec-Université Laval, Pathology, Québec, Canada
  6. 6Chu De Québec-Université Laval, Gynecology Oncology Service, Québec, Canada
  7. 7The University of British Columbia, Vancouver General Hospital, Pathology and Laboratory Medicine, Vancouver, Canada


Introduction/Background*The role of lymph node (LN) assessment in endometrial cancer (EC) has been a subject of debate for decades, with significant variation in use between centres. Molecular classification of EC provides objective, prognostic information and be performed on diagnostic endometrial biopsy specimens. The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) uses targeted next-generation sequencing to detect pathogenic POLE exonuclease domain mutations (POLEmut) and immunohistochemistry to evaluate for the presence of mismatch repair deficiency (MMRd), TP53 mutations (p53abn) or tumours with no specific molecular profile (NSMP/p53wt). Herein, we assessed the association between EC molecular subtype and LN metastases in a single institutional cohort with a uniform approach to LN assessment.

Methodology All ECs treated with primary surgery from a single institution in 2015 underwent ProMisE molecular subtyping and collection of clinicopathologic and outcomes data.

Result(s)*Complete pelvic and para-aortic lymphadenectomies were performed in 171 of 172 consecutive cases of EC. The distribution of ProMisE subtypes and clinicopathologic features associated with molecular subtype are outlined in table 1. The p53abn subtype was observed across a range of EC histotypes, including low grade endometrioid endometrial carcinoma. LN metastases were found in 31/171 (18.1%) patients: pelvic only in 83.9% and pelvic plus para-aortic in 16.1%. LN metastases included macrometastases (19/31), micrometastases (5/31), and isolated tumour cells (ITCs) (7/31).

Molecular subtype was significantly associated with LN metastases (p=0.004); there was a strong association between LN metastases and p53abn EC (nodal involvement in 44.8% of cases). LN metastases were observed in 14.2% of POLEmut, 14.9% of MMRd, and 10.8% of NSMP EC.

By multivariate analysis, molecular subtype and CA 125 >25 kU/L were significantly associated with LN metastases (p=0.021 and p=0.022 respectively) compared to histotype, which showed no significant association with LN status (p=0.24).

Abstract 223 Table 1

Summary of the clinicopathologic features by ProMisE molecular subtype

Conclusion*EC molecular subtype significantly associates with LN metastases and offers objective, reproducible, and prognostic information from diagnostic specimens. Pre-operative knowledge of molecular subtype can guide biologically-informed approaches to LN sampling, particularly for patients with high molecular risk (p53abn) EC.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.